New Non-mRNA Vaccine Approved

New Non-mRNA Vaccine Approved

( – As the pandemic continues to affect the world, scientists are still trying to develop vaccines and medicines to minimize the impact of COVID-19. On February 24, the Canadian government announced it approved a new non-mRNA 2-dose vaccine for adults aged 18 to 64. Health Canada claimed the vaccine is 71% effective against the coronavirus and 100% effective against severe COVID-19 symptoms. In addition, the healthcare organization asserts the plant-based vaccine works against many variants, including Delta and Omicron.

Medicago ran three clinical trials with Covifenz, but Health Canada’s approval depends on the company’s continued monitoring and reporting for safety and efficacy. Unfortunately, the company didn’t receive many volunteers over 65, but they plan to gather participants in that age group. They also plan to test Covifenz as a booster for children.

The vaccine development company used plants to make non-infectious particles that act like the virus itself, prompting the human body to produce antibodies against the coronavirus. They don’t use animal products in their vaccine, instead opting for recombinant technology and genetic sequencing.

Medicago will seek approval in Japan and possibly the United States, the rest of Asia, and Europe.

Copyright 2022,